Sana Health
Military Operational Medicine funded for PTSD, Adjustment Disorder and Pain and Sleep (over $5m). 3 trials in progress. Sana Health is an FDA Breakthrough Designated Device, currently in front of the FDA for Neuropathic Pain as a de novo - expecting to be on market Q4 2025. Sana is a wearable audiovisual neuromodulation device, that provides anxiety and pain relief, and sleep on demand. $25m raised to date, and in the middle of a Series A extension SAFE note round.
Sana Health is currently seeking investment
Sana Health is seeking a series-a investment in the range of 1m-5m
What We Do
CEO made the first Sana device to solve my life threatening levels of neuropathic pain resulting from driving a jeep off a bridge near Sana'a in Yemen. The first version of the device wiped out my own pain permanently in 3 months. Here is a short background video; https://www.sana.io/bbc-video. Sana is an FDA Breakthrough Designated Device (BDD). It is a wearable headset that uses audio-visual neuromodulation – pulses of light and sound – to generate specific frequency patterns in the brain, providing anxiety relief on demand. This gives us multiple applications across pain and mental health, where current drug solutions have harsh long-term side effects and addiction risks. Denovo Neuropathic Pain FDA approval expected Q3/Q4 2025 In the US, DoD funded for PTSD ($4.5m), Adjustment Disorder ($550k), and Pain& Sleep ($500k). (Covers 60% of monthly burn) PTSD and Pain study being run in Israel by Chair of National Council for PTSD. (Israel sales expected in 2025) Expected VA + Israel sales + reimbursement under NoPain Act Currently raising a Series A extension SAFE note round $33m Cap ($2.7m closed $2.3m open) . Expected Series B equity raise at $100m valuation. Would love to talk with anyone interested in the current round!
Psychological and Cognitive Health and Performance
FDA Regulated Medical Devices
Application Area
Regenerative Medicine
Key People
Funded Projects
Sana Health publishes first peer-reviewed article exploring the effectiveness of Sana device in managing PTSD in MTEC/MOMRP/VA study
Researchers found that combining the Sana Device with standard PTSD treatments significantly improved symptoms, anxiety, depression, and quality of life in veterans, outperforming treatment alone. This non-invasive, drug-free technology offers a promising mental health tool. A $3.4M follow-up study is underway, with broader trials and FDA approval efforts in progress.
News & Updates
Funded by the Department of Defense for PTSD
Sana Health has received funding from the Department of Defense to support its initiatives related to PTSD.
Pivotal Neuropathic Pain data submitted to the FDA for market approval
Sana Health has submitted pivotal data to the FDA for market approval regarding its device's effectiveness in treating neuropathic pain.